Savara Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Savara wird ein Gewinn- und Umsatzwachstum von 55.7% bzw. 66.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 55.9% pro Jahr wachsen soll.

Wichtige Informationen

55.7%

Wachstumsrate der Gewinne

55.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.2%
Wachstumsrate der Einnahmen	66.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SVRA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	59	-29	-82	N/A	5
12/31/2025	3	-86	-86	N/A	7
12/31/2024	N/A	-85	-79	N/A	7
6/30/2024	N/A	-75	-72	-72	N/A
3/31/2024	N/A	-64	-60	-60	N/A
12/31/2023	N/A	-55	-51	-51	N/A
9/30/2023	N/A	-49	-44	-44	N/A
6/30/2023	N/A	-43	-39	-39	N/A
3/31/2023	N/A	-40	-38	-38	N/A
12/31/2022	N/A	-38	-35	-35	N/A
9/30/2022	N/A	-39	-35	-35	N/A
6/30/2022	N/A	-39	-36	-36	N/A
3/31/2022	N/A	-41	-39	-39	N/A
12/31/2021	N/A	-43	-40	-40	N/A
9/30/2021	0	-45	-43	-43	N/A
6/30/2021	0	-46	-41	-41	N/A
3/31/2021	0	-44	-36	-36	N/A
12/31/2020	0	-50	-43	-40	N/A
9/30/2020	0	-68	-41	-37	N/A
6/30/2020	N/A	-69	-45	-42	N/A
3/31/2020	N/A	-81	-51	-47	N/A
12/31/2019	N/A	-78	-45	-45	N/A
9/30/2019	N/A	-57	-46	-46	N/A
6/30/2019	N/A	-57	-43	-43	N/A
3/31/2019	N/A	-47	-41	-40	N/A
12/31/2018	N/A	-62	-39	-39	N/A
9/30/2018	N/A	-58	-39	-38	N/A
6/30/2018	N/A	-52	-38	-38	N/A
3/31/2018	N/A	-53	N/A	-35	N/A
12/31/2017	N/A	-31	N/A	-28	N/A
9/30/2017	0	-28	N/A	-21	N/A
6/30/2017	0	-25	N/A	-16	N/A
3/31/2017	0	-14	N/A	-9	N/A
12/31/2016	0	-11	N/A	-8	N/A
12/31/2015	0	-9	N/A	-5	N/A
12/31/2014	2	-6	N/A	-4	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SVRA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: SVRA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: SVRA wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: SVRADie Einnahmen des Unternehmens (66.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: SVRADie Einnahmen des Unternehmens (66.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SVRA in 3 Jahren voraussichtlich hoch sein wird

Savara Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 19% to US$10.71

No longer forecast to breakeven

Forecast to breakeven in 2026

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

Recent updates

Savara: Trial Successful, But I'm Only Half Convinced

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024

No longer forecast to breakeven

New minor risk - Profitability

Chairman & CEO recently sold US$396k worth of stock

Forecast to breakeven in 2026

Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

New minor risk - Profitability

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

New minor risk - Shareholder dilution

New minor risk - Share price stability

Savara Inc. has completed a Follow-on Equity Offering in the amount of $79.994334 million.

Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis

Independent Director recently bought US$259k worth of stock

No longer forecast to breakeven

Price target increased by 21% to US$4.60

Savara Inc. Announces New Leadership Appointments

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara Inc. Announces New Leadership Appointments

Independent Director recently bought US$56k worth of stock

Forecast to breakeven in 2025

Independent Director recently bought US$82k worth of stock

Independent Director recently bought US$68k worth of stock

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Independent Director recently bought US$187k worth of stock

Independent Director recently bought US$142k worth of stock

Savara Announces Resignation of Badrul Chowdhury as Chief Medical Officer, Effective on September 9, 2022

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Savara GAAP EPS of -$0.06 in-line

Independent Director recently bought US$138k worth of stock

Savara Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Savara Inc., Annual General Meeting, Jun 02, 2022

Price target increased to US$4.50

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Independent Director recently bought US$64k worth of stock

Independent Director recently bought US$215k worth of stock

Independent Director recently bought US$176k worth of stock

Independent Director recently bought US$115k worth of stock

Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara Inc. Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000E Value Index

Savara: They Failed Once, But They Are Trying Again

Independent Director recently bought US$81k worth of stock

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Savara Inc. has completed a Follow-on Equity Offering in the amount of $113.011275 million.

Revenue and earnings beat expectations

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Chairman & CEO recently bought US$50k worth of stock

New 90-day high: US$2.06

New 90-day high: US$1.97

New 90-day high: US$1.57

Price target lowered to US$2.67

Savara Inc. Provides Update on Molgradex in aPAP and the Phase 3 IMPALA 2 Trial

Savara Inc. Announces CEO Change

New 90-day high: US$1.44

Price target lowered to US$3.83

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

New 90-day low: US$1.00

Earnings beat expectations